131 related articles for article (PubMed ID: 36208247)
61. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.
Jo JH; Chung HW; Kim SY; Lee MH; So Y
Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943
[TBL] [Abstract][Full Text] [Related]
62. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
Lee JW; Oh D; Eom KY; Kim JH; Kim WC; Chung MJ; Lee JH
Clin Exp Metastasis; 2020 Feb; 37(1):125-131. PubMed ID: 31555945
[TBL] [Abstract][Full Text] [Related]
63. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
[TBL] [Abstract][Full Text] [Related]
64. Interim 18F-FDG PET/CT and BCL2 for predicting the prognosis of patients with diffuse large B-cell lymphoma in the rituximab era.
Jiang M; Chen P; Ruan X; Xu W; Li T; Wu L; Zhou W; Wu H; Wang Q
Nucl Med Commun; 2018 Feb; 39(2):147-153. PubMed ID: 29189488
[TBL] [Abstract][Full Text] [Related]
65.
Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
[TBL] [Abstract][Full Text] [Related]
66. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
[TBL] [Abstract][Full Text] [Related]
67. Interim
Jiang M; Chen P; Ruan X; Ye X; Pan Y; Zhang J; Huang Q; Zhou W; Wu H; Wang Q
Oncol Lett; 2017 Dec; 14(6):6715-6723. PubMed ID: 29344120
[TBL] [Abstract][Full Text] [Related]
68. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
Ying ZT; Mi L; Wang XJ; Zhang YW; Yang Z; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):382-386. PubMed ID: 29779346
[No Abstract] [Full Text] [Related]
69. Predictive value of baseline
Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K
Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253
[TBL] [Abstract][Full Text] [Related]
70. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
71. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
[TBL] [Abstract][Full Text] [Related]
72. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
[TBL] [Abstract][Full Text] [Related]
73. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.
Broecker-Preuss M; Becher-Boveleth N; Müller SP; Hüttmann A; Hanoun C; Grafe H; Richter J; Klapper W; Rekowski J; Bockisch A; Dührsen U
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2611-2621. PubMed ID: 34708297
[TBL] [Abstract][Full Text] [Related]
74. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.
Alzahrani M; El-Galaly TC; Hutchings M; Hansen JW; Loft A; Johnsen HE; Iyer V; Wilson D; Sehn LH; Savage KJ; Connors JM; Gascoyne RD; Johansen P; Clasen-Linde E; Brown P; Villa D
Ann Oncol; 2016 Jun; 27(6):1095-1099. PubMed ID: 27002106
[TBL] [Abstract][Full Text] [Related]
75. Development and validation of a [
Li M; Yao H; Zhang P; Zhang L; Liu W; Jiang Z; Li W; Zhao S; Wang K
Eur Radiol; 2023 May; 33(5):3354-3365. PubMed ID: 36547676
[TBL] [Abstract][Full Text] [Related]
76. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
Toledano MN; Vera P; Tilly H; Jardin F; Becker S
PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
[TBL] [Abstract][Full Text] [Related]
77. Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphoma.
Adams HJA; de Klerk JMH; Fijnheer R; Heggelman BGF; Dubois SV; Nievelstein RAJ; Kwee TC
Eur J Radiol; 2016 Jan; 85(1):304-309. PubMed ID: 26515992
[TBL] [Abstract][Full Text] [Related]
78. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
79. [Prognostic value of maximum standard uptake on pretreatment 18F-FDG PET/CT scan in newly diagnosed diffuse large B cell lymphoma].
Ying ZT; Wang XJ; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ping LY; Liu WP; Deng LJ; Zhang C; Yang Z; Zhu J
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3246-9. PubMed ID: 23328506
[TBL] [Abstract][Full Text] [Related]
80. [¹⁸F-FDG PET/CT for predicting outcomes of diffuse large B-cell lymphoma: shall it be performed in the interim versus later phase of chemotherapy?].
Li H; Wu H; Wang Q; Li H; Zhou W; Tian Y; Dong Y
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):208-12. PubMed ID: 25736114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
